BioSante Pharmaceuticals, Inc. (BPAX)

[Just the facts maam]

Connecting the Libigel Dots.

Seeing that Libigel has a target audience of up to 9 million , according to page 17 of Biosante's Market Data presentation

And

Today, an estimated 50 million women in the United States have reached menopause. Most women will spend at least one-third of their lives in or beyond menopause. With an average life expectancy expectancy over 80 years. That equates to over 26 years of post menopause per person. Post menopause is considered a risk factor in Heart Disease

Post Menopause

Heart Disease Risk Factors in Women

Now look at the most recent patent application in relation to Libigel including:

- Methods for decreasing cardiovascular risk in postmenopausal women

- Methods for treating sexual dysfunction while decreasing cardiovascular risk

- COMMERCIAL SCALE PRODUCTION METHODS FOR TRANSDERMAL HORMONE FORMULATIONS

Libigel Patents


By following the trail I have just provided, Libigel is one safety result (and the regulatory process) away from becoming a very lucrative product.

Note: Libigel is still being evaluated for cognitive benefits in Australia and I have not mentioned the proven testosterone replenishment market including targeting Osteoporosis.

Biosante and Libigel have many options, they will continue with HSDD and compliment that with the other target audiences. Even if HSDD does not fly Libigel has potentially become over 465% more lucrative then its original intention and if HSDD is accepted, Libigel only becomes more valuable.